Article in Radiology. Cardiothoracic imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 6 countries.
Johannes UhligDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0003-3557-3194
Omar Al-BouriniDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0001-9405-9801
Rodrigo SalgadoDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0003-4060-1612
Marco FranconeDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0002-7906-3420
Rozemarijn VliegenthartDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0002-7262-3376
Jens BremerichDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0002-1002-8483
Joachim LotzDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).ORCID 0000-0002-1412-2741
Matthias GutberletDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).
Antwerp University Hospital · BEUniversity Hospital of Basel · CHUniversity Medical Center Groningen · NLYale University · US
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
purposeTo assess current use and acute safety profiles of gadolinium-based contrast agents (GBCAs) in cardiac MRI given recent suspensions of GBCA approval. MATERIALS AND
methodsPatients were retrospectively included from the multinational multicenter European Society of Cardiovascular Radiology (ESCR) MR/CT Registry collected between January 2013 and October 2019. GBCA-associated acute adverse events (AAEs) were classified as mild (self-limiting), moderate (pronounced AAE requiring medical management), and severe (life threatening). Multivariable generalized linear mixed-effect models were used to assess AAE likelihood.
resultsA total of 154 779 patients (average age, 53 years ± 19 [standard deviation]; 99 106 men) who underwent cardiac MRI were included, the majority of whom underwent administration of GBCAs (94.2% [
conclusionGadolinium-based contrast agent administration changed according to recent regulatory decisions, with use of macrocyclic agents almost exclusively in 2018 and 2019; these agents also demonstrated a favorable acute safety profile.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Gadolinium-based Contrast Agents for Cardiac MRI: Use of Linear and Macrocyclic Agents with Associated Safety Profile from 154 779 European Patients. · full record | OpenQuestion